CASI Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own4.70% Shs Outstand13.80M Perf Week-8.25%
Market Cap37.42M Forward P/E- EPS next Y-1.51 Insider Trans16.19% Shs Float11.55M Perf Month-25.07%
Income-31.40M PEG- EPS next Q-0.56 Inst Own1.80% Short Float1.42% Perf Quarter-60.62%
Sales33.50M P/S1.12 EPS this Y38.40% Inst Trans-16.25% Short Ratio2.51 Perf Half Y-65.25%
Book/sh5.44 P/B0.51 EPS next Y58.80% ROA-22.90% Target Price37.00 Perf Year-81.47%
Cash/sh2.79 P/C1.00 EPS next 5Y- ROE-36.80% 52W Range2.69 - 17.40 Perf YTD-65.25%
Dividend- P/FCF- EPS past 5Y-9.70% ROI-50.50% 52W High-84.31% Beta0.74
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin58.30% 52W Low1.45% ATR0.40
Employees168 Current Ratio3.80 Sales Q/Q59.60% Oper. Margin- RSI (14)36.10 Volatility6.18% 6.53%
OptionableNo Debt/Eq0.00 EPS Q/Q44.00% Profit Margin-93.60% Rel Volume0.64 Prev Close2.78
ShortableYes LT Debt/Eq0.00 EarningsMay 12 BMO Payout- Avg Volume65.47K Price2.73
Recom1.30 SMA20-10.59% SMA50-25.74% SMA200-64.19% Volume38,996 Change-1.80%
May-18-21Initiated BTIG Research Buy $4
Apr-26-21Initiated Mizuho Buy $3.80
Oct-23-20Initiated Oppenheimer Outperform $5
Sep-22-16Initiated Maxim Group Buy $4
Oct-29-15Resumed H.C. Wainwright Buy $2.50 → $3
Jun-23-15Initiated H.C. Wainwright Buy $2.50
Jun-02-22 06:34AM  
May-26-22 04:30PM  
May-25-22 07:53AM  
May-24-22 07:00AM  
May-12-22 08:15AM  
May-10-22 09:25AM  
May-02-22 10:15AM  
Apr-01-22 07:27AM  
Mar-31-22 07:15PM  
Mar-28-22 07:00AM  
Mar-23-22 07:00AM  
Mar-04-22 07:00AM  
Feb-23-22 04:36AM  
Feb-16-22 07:00AM  
Feb-15-22 05:03PM  
Jan-20-22 08:50AM  
Jan-18-22 07:00AM  
Jan-09-22 07:28AM  
Jan-03-22 07:00AM  
Dec-17-21 07:00AM  
Dec-10-21 07:15AM  
Nov-25-21 04:34AM  
Nov-22-21 07:17AM  
Nov-15-21 07:00AM  
Nov-12-21 07:00AM  
Nov-05-21 07:00AM  
Nov-02-21 07:00AM  
Nov-01-21 03:01PM  
Oct-25-21 07:50AM  
Oct-06-21 07:17AM  
Sep-27-21 02:01PM  
Sep-20-21 07:00AM  
Aug-23-21 09:58AM  
Aug-14-21 03:10AM  
Aug-12-21 10:05AM  
Aug-10-21 07:00AM  
Aug-02-21 03:01PM  
Jul-25-21 03:49AM  
Jun-10-21 07:00AM  
May-27-21 07:00AM  
May-17-21 10:20AM  
May-13-21 07:00AM  
May-11-21 07:00AM  
Apr-28-21 10:39AM  
Apr-26-21 02:11AM  
Mar-30-21 07:00AM  
Mar-24-21 03:57PM  
Mar-23-21 04:01PM  
Mar-11-21 04:30PM  
Mar-08-21 10:17AM  
Feb-25-21 12:08AM  
Feb-16-21 07:00AM  
Jan-28-21 07:00AM  
Jan-21-21 07:00AM  
Jan-11-21 12:17AM  
Jan-08-21 07:00AM  
Dec-23-20 07:00AM  
Dec-16-20 07:00AM  
Dec-12-20 02:20PM  
Nov-30-20 09:05AM  
Nov-26-20 11:16PM  
Nov-18-20 09:00PM  
Nov-09-20 10:30PM  
Nov-06-20 06:14AM  
Nov-05-20 07:00AM  
Oct-27-20 07:00AM  
Oct-02-20 07:00AM  
Sep-29-20 07:00AM  
Sep-11-20 07:00AM  
Sep-07-20 08:28AM  
Aug-26-20 05:31AM  
Aug-11-20 11:30AM  
Aug-10-20 07:29AM  
Jul-22-20 09:05AM  
Jul-21-20 04:01PM  
Jul-09-20 09:39AM  
Jun-08-20 07:00AM  
Jun-02-20 07:00AM  
May-31-20 05:38PM  
May-25-20 06:14AM  
May-14-20 06:47AM  
May-12-20 06:43AM  
May-11-20 07:00AM  
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
He Wei-WuChairman and CEOJun 15Buy3.1850,000159,000644,553Jun 17 04:14 PM
He Wei-WuChairman and CEOJun 14Buy3.062,0966,414594,553Jun 17 04:14 PM
He Wei-WuChairman and CEOJun 13Buy2.9736,058107,092592,457Jun 17 04:14 PM
He Wei-WuChairman and CEONov 18Buy0.98200,000196,0005,558,472Nov 19 04:10 PM
He Wei-WuChairman and CEONov 17Buy0.99200,000198,0005,362,569Nov 19 04:10 PM
He Wei-WuChairman and CEOAug 19Buy1.26180,000226,8005,163,994Aug 20 04:27 PM
He Wei-WuChairman and CEOAug 18Buy1.29300,000387,0004,983,994Aug 20 04:27 PM